AstraZeneca still aiming for Oxford Covid-19 vaccine by year-end, says CEO

AstraZeneca Plc Chief Executive Officer Pascal Soriot said the coronavirus vaccine the company is developing with the University of Oxford could still be ready before the end of the year after pausing its trials due to a possible serious neurological problem in one participant.
 

Speaking at an online conference Thursday, Soriot sought to reassure investors after the company and its partner confirmed earlier this week that they had temporarily stopped giving people the experimental shot.
 

The trial was halted after a person in the UK who was participating in it got sick, triggering a review of safety data. Though such